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ABSTRACT
MECP2, a relatively small gene located in the human
X chromosome, was initially described with three
exons transcribing RNA from which the protein
MeCP2 was translated. It is now known to have
four exons from which two isoforms are translated;
however, there is also evidence of additional func-
tional genomic structures within MECP2, including
exons potentially transcribing non-coding RNAs.
Accompanying the recognition of a higher level of
intricacy within MECP2 has been a recent surge
of knowledge about the structure and function of
human genes more generally, to the extent that
the definition of a gene is being revisited. It is
timely now to review the published and novel func-
tional elements within MECP2, which is proving to
have a complexity far greater than was previously
thought.
INTRODUCTION
Anatomy of atypical gene
To perform their biological role, most well-characterized
genes are expressed as protein, although it is now recog-
nized that genes also transcribe a diverse array of non-
coding RNAs (1). A typical eukaryotic gene, in addition
to coding regions and protein domains, has a number of
functional elements that play roles in transcription, post-
transcriptional modiﬁcation and translation. Exons,
introns and 50- and 30-untranslated regions (UTRs)
deﬁne the ‘skeleton’ of the gene, but a gene is also asso-
ciated with sequences inﬂuencing splicing, regulatory ele-
ments such as promoters, enhancers, suppressors and
CpG islands, at least one polyadenylation signal in the
30-UTR, and transcription and translation initiation and
termination sites. In addition to recognized functional ele-
ments, many genes also contain blocks of genomic
sequence deep within introns that are highly conserved
across species. The preservation of these sequence blocks
strongly suggests that they have important functions that
are yet to be deﬁned.
Upgradedconcept of aeukaryotic gene
Until recently, insights into the roles of the multiple com-
ponents within a gene, particularly the many sequence-
speciﬁc functional elements in non-coding areas, have
been limited. This is now changing quickly with many
new insights emerging from the pilot project phase of
the Encyclopaedia Of DNA Elements (ENCODE) project
(2). ENCODE aims to produce a functional annotation of
the human genome, beginning with a targeted  1% of
the genome, including MECP2, for the pilot project.
ENCODE is generating a vast quantity of new informa-
tion about the transcriptional proﬁles of sequences within
the targeted regions in diﬀerent tissues and cell lines. The
ENCODE output is also deﬁning regions likely to contain
functional regulatory elements based on features of chro-
matin structure, such as histone modiﬁcations and DNase
I hypersensitivity sites, as well as binding sites of regula-
tory proteins. Measures of the extent of evolutionary con-
servation and secondary-structure predictions also help to
highlight regions likely to be functionally relevant (2).
The ENCODE ﬁndings have provoked a fundamental
reassessment of the concept of a gene (3,4). The term
‘gene’ was ﬁrst coined by Johannsen in 1909 (5) to encap-
sulate Gregor Mendel’s notion of a unit of heredity.
Prompted particularly by studies of the segregation of
mutations in Drosophila, which gave rise to the hypothesis
that genes are structured as discrete elements organized in
a linear array (6), the concept of a gene as a calculating
unit transformed over time to the notion of a material unit
with both structure and function. Recognition that gene
mutations may cause inborn errors of metabolism
strengthened the idea of a gene as a functional unit, or
‘one gene, one enzyme’ (7). The concept of a gene being a
blueprint for a protein was strengthened in the 1950s when
it was demonstrated that heritable information is stored in
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the crucial link between the physical structure of a gene
within DNA and its functional protein products. In the
last decade the view of genes as discrete, linearly arranged
loci that generally encode a protein has evolved further
with ongoing revelations regarding the structure, organi-
zation and functions of genes (3,4,8). Now ENCODE and
others (9) have demonstrated that transcription is far
more extensive than previously anticipated. Transcripts
from the same and opposite strands often overlap,
making it diﬃcult to deﬁne discrete boundaries separating
genes from one another. Furthermore, many novel tran-
scribed regions have been detected in intergenic and intro-
nic sequences. Recognition that many newly identiﬁed
transcripts, including those from protein-coding loci,
have tissue-speciﬁc expression but limited coding potential
has spawned the now fast-growing interest in regulatory
non-protein-coding RNAs (2).
Novel features identiﬁed within MECP2 by the pilot
phase of ENCODE help illustrate these emerging insights.
As shown in Figure 1, 50 rapid ampliﬁcation of cDNA ends
(50-RACE) has extended the known 50-terminal of MECP2
further upstream, and also identiﬁed transcripts that con-
nect downstream genes with the 30-UTR of MECP2,o r
with genes upstream of MECP2 (10; http://genome.ucs-
c.edu/). Novel transcribed regions identiﬁed by 50-RACE
appear to be expressed in a tissue-speciﬁc manner, which
raises the spectre of a diversity of previously unrecognized
tissue-speciﬁc functions. Such ﬁndings across the
ENCODE regions have prompted suggestions that a
gene should be deﬁned not at the DNA level, but rather
at the level of its functional products, whether RNA or
protein (3,4).
MECP2 INRELATION TO OTHER HUMAN GENES
There is great diversity in the size and complexity of
human genes. The dystrophin gene, for example, has 79
exons spanning over 2.3 million base pairs (11). To begin
examining the structural features of a gene using the
example of dystrophin would indeed be a daunting task.
By contrast, the MECP2 gene with only four published
exons (12) oﬀers a more tractable opportunity to summar-
ize the currently discernible functional components of a
multi-exonic gene. In addition, as an X-linked gene subject
to X inactivation (13–15), the impact of mutations within
MECP2 is generally easier to characterize than mutations
in most autosomal genes. It is becoming increasingly evi-
dent, however, that MECP2 has a higher level of complex-
ity than originally believed. MECP2 has some remarkable
features, most notably the extent of its 30-UTR (12,16),
which is one of the longest known in the human
genome. It also contains several polyadenylation signals
that give rise to transcripts of diﬀerent lengths with diﬀer-
ent expression patterns (12,14,16,17). The second intron
of MECP2, traversing almost 60000 nucleotides, is
atypically long and contains several regions with notable
evolutionary conservation (12; http://genome.ucsc.edu/).
Alternative transcripts in addition to those reported in
the literature have been identiﬁed by the ENCODE
Figure 1. ENCODE data reveals increased transcriptional complexity within MECP2. This screenshot from the March 2006 assembly of the UCSC
Genome Browser (http://genome.ucsc.edu/) compares the previously annotated MECP2 gene structure (RefSeq-annotated genes) with the
GENCODE annotation (v3.1, March 2007). The tracks ‘GENCODE RACEfrags’ show the mapped locations of 50-RACE products from a
range of tissues (83). Also displayed is the Aﬀymetrix data representing the genomic source and relative abundance of RNA transcripts detected
in the cytoplasm of HeLa cells.
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The emerging details from ENCODE are yielding more
insight into the function and regulation of MECP2 expres-
sion, as well as pinpointing genomic sites where previously
unrecognized disease-causing mutations could occur. For
these reasons it is timely to conduct a detailed reassess-
ment of the MECP2 genomic sequence. We integrate here
the data made available by the ENCODE project with the
previously published features of the MECP2 gene.
Insights gathered from this relatively small human gene
have the potential to yield lessons that may have relevance
to larger, more complex genes.
BIOLOGICAL FUNCTIONS OF MECP2
MeCP2 was ﬁrst identiﬁed as a protein capable of binding
to methylated DNA (18), although it was soon noted to
have a weaker aﬃnity for unmethylated DNA as well
(19,20). MeCP2 diﬀers from its other methyl-DNA-
binding family members (21,22), by its speciﬁc and high-
aﬃnity binding to symmetrically methylated CpG dinu-
cleotides (18). More recently, it has been recognized that
MeCP2 requires an A/T run of four or more bases adja-
cent to the methyl-CpG for eﬃcient DNA binding (23). As
DNA methylation was known to be an important
mechanism for regulating gene expression (24) and
MeCP2 had been shown to localize to heterochromatin
(18,25), it seemed likely, and was soon conﬁrmed, that
MeCP2 could function as a transcriptional repressor
(26). Although initially described as a global transcrip-
tional repressor, a limited number of targets of MeCP2-
mediated regulation have now been identiﬁed (Table 1).
The most well-established mechanism by which MeCP2 is
able to repress transcription involves the recruitment of
co-repressor complexes containing histone deacetylases
that are able to alter chromatin structure (27–29).
However, as trichostatin A, a histone deacetylase inhibi-
tor, does not entirely relieve the transcriptional repression
conferred by MeCP2 (27,28), it is evident that MeCP2
must also be able to regulate transcription inde-
pendently of HDACs, and several such HDAC-
independent mechanisms have been proposed. Kaludov
and Wolﬀe (30) demonstrated that MeCP2 is still able to
repress transcription in vitro in the absence of histones by
interacting with transcription factor IIB (TFIIB) to pre-
vent assembly of the pre-initiation complex. MeCP2 may
also interact with other chromatin-modifying enzymes or
complexes, including histone methyltransferase (31), Brm
and SWI/SNF (32) and ATRX (33). MeCP2 may also be
able to directly inﬂuence chromatin structure. MeCP2
binds to methylated linker DNA in nucleosome arrays
(34) and induces chromatin compaction in vitro by med-
iating nucleosome–nucleosome interactions. Interestingly,
MeCP2 also mediates conformational changes in naked
DNA in vitro, including cross-linking of two or more
DNA molecules (35–37). Consistent with its role as a chro-
matin-binding protein, MeCP2 was shown to be capable
of binding to four-way DNA junctions, a property that is
shared by several other proteins including HP1, HMGB1
and the SWI/SNF complex (38). The interaction of
MeCP2 with chromatin is transient and dynamic, as
demonstrated by rapid recovery of ﬂuorescence after
photobleaching (39). It is also proposed that MeCP2
may be involved in the formation of a chromatin loop at
the Dlx5 and Dlx6 genes that results in silencing of these
genes. Horike et al. (40) identiﬁed a MeCP2-binding site
near Dlx5 and Dlx6, and observed that transcript levels
from each of these genes were elevated 2-fold in the frontal
cortex of Mecp2-null mice when compared to wild type.
They went on to perform chromatin conformation capture
(3C) assays and concluded that normal silencing of Dlx5
and Dlx6 was the result of a chromatin loop that was not
detected in Mecp2-null cells, suggesting that MeCP2
mediated formation of this loop. While MeCP2 may be
able to form such structures, at least in vitro, Schule et al.
(41) have been unable to detect a reproducible or signiﬁ-
cant increase in expression of Dlx5 and Dlx6 in the frontal
cortex of Mecp2-null mice. As a result, the role of MeCP2
in the silencing of these genes is now in doubt, although
MeCP2-binding sites within the DLX5/DLX6 locus have
been conﬁrmed by independent chromatin-immunopreci-
pitation (ChIP) assays (42).
A recent study of MeCP2-binding sites within a human
neuronal cell line has also provided evidence that MeCP2
Table 1. MeCP2 target genes
Gene Function References
xHairy2a Neuronal repressor (56)
BDNF/Bdnf Long term potentiation (81,90)
IGF2 Cell proliferation (91)
MPP1 Signal transduction (91)
UBE3A/Ube3a Proteolysis (92,93)
GABRB3/Gabrb3 GABA receptor subunit (92)
DLX5/Dlx5 Transcription factor (40)
Dlx6 Transcription factor (23,40)
Fkbp5 Hormone signalling (94)
Sgk1 Ion channel activation (94)
ID1/Id1, ID2/Id2, ID3/Id3 Transcriptional regulation (95)
Uqcrc1 Mitochondrial respiratory
complex subunit
(59)
Crh Anxiety and stress response (96)
IGFBP3/Igfbp3 Hormone signalling (97)
FXYD1/Fxyd1 Na
+/K
+-ATPase activity (98,99)
Reln Cell signalling (99)
Gtl2/Meg3 Non-coding RNA (99)
JUNB Early response gene,
Oncogene
(42)
RNASEH2A Ribonucleotide cleavage from
RNA–DNA complex
(42)
Sst Hormone signalling (43)
Oprk1 Opioid receptor (43)
Gamt Methyltransferase (43)
Gprin1 Neurite formation (43)
Mef2c Myogenesis (43)
A2bp1 Splicing (43)
Creb1 Transcriptional co-activator (43)
The table includes genes shown to bind MeCP2/xMeCP2 directly and
with expression that is altered in the presence of dysfunctional MeCP2/
xMeCP2. It should be noted, however, that independent studies have
not conﬁrmed MeCP2-mediated regulation of DLX5/Dlx5 and Dlx6
(41) and Ube3a (100). Furthermore, there are some inconsistencies in
the results of the groups identifying UBE3A/Ube3a (92,93) and
FXYD1/Fxyd1 (98,99) as MeCP2 targets. Sst, Oprk1, Gamt, Gprin1
and Creb1 are reported to be activated by MeCP2 (43).
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mediated by binding to methylated promoters (42).
In this analysis, ChIP assays revealed that CpG islands
and transcriptionally silent promoters constitute only
a minority of MeCP2-binding sites. Instead, a large
number of MeCP2-binding sites are intergenic, consistent
with a role for MeCP2 in long-range chromatin modiﬁca-
tions. Another interesting observation from this analysis
was a correlation between MeCP2 and RNA polymerase II
binding sites, which suggests that MeCP2 often binds to
transcriptionally active promoters. In this setting, MeCP2
may be functioning to downregulate rather than comple-
tely silence gene expression from these promoters, as
appears to be the case for JUNB (42). Alternatively,
Chahrour et al. (43) have recently proposed that MeCP2
can function as a transcriptional activator. This hypothesis
arose from observations that a large number of genes were
downregulated in the hypothalami of Mecp2-null mice but
upregulated in transgenic Mecp2-overexpressing mice rela-
tive to wild-type controls, a result that contradicts the idea
of MeCP2 as a transcriptional repressor. Chahrour et al.
(43) went on to conﬁrm binding of MeCP2 to the promoter
regions of four of these activated genes. Furthermore,
they showed that MeCP2 co-immunoprecipitates the
co-activator CREB-1 and that both MeCP2 and CREB-1
binding were enriched at the Sst promoter, one of the pre-
sumed targets of MeCP2-mediated activation. Thus, it
appears that MeCP2 may be more correctly referred to
as a transcriptional modulator than a transcriptional
repressor. If MeCP2 is indeed able to activate as well as
repress transcription, it will be interesting to identify which
regions of the MeCP2 protein are involved in the recruit-
ment of transcriptional co-activators and how MeCP2 is
able to speciﬁcally recruit co-repressors in some instances
and co-activators in others.
Beyond a role in transcriptional regulation, MeCP2 has
also been implicated in alternative splicing as part of an
RNA-protein complex (44,45), and genome-wide altera-
tions in RNA splicing have been observed in mice with
MeCP2 dysfunction (45). The recent delineation of at least
six biochemically distinct domains within MeCP2
(Figure 2), along with the recognition that MeCP2 has a
disordered tertiary structure potentially allowing diﬀerent
combinations of domains to act together for speciﬁc func-
tions (46), provide a strengthened framework for under-
standing the various structural elements within this
multifunctional protein.
MECP2 DYSFUNCTION
MeCP2 shows complex spatial and temporal patterns of
distribution, and both up- and down-regulation of MeCP2
may have disastrous consequences. Mutations in MECP2
resulting in loss-of-function are implicated in several
neurological disorders including Rett Syndrome (RTT),
which is a severe neurodevelopmental disorder
Figure 2. MECP2 coding regions and functional protein domains. The four annotated exons of the MECP2 gene are magniﬁed and their coding
portions are shown in colour, with the non-coding portions represented in grey. The MeCP2_e1 and MeCP2_e2 isoforms are also displayed. The
30-UTR, with four alternative polyadenylation signals, and the 50-UTR of each transcript are also shown. The positions of the well-characterized
MBD, TRD and nuclear localization signals of the MeCP2 protein as well as the more-recently identiﬁed WDR and RG repeat region are
as labelled. The distinct tertiary structures and functional domains deﬁned by trypsin cleavage sites (46) are also indicated.
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cally by a period of seemingly normal development
followed by the onset of decelerating developmental mile-
stone achievements and brain growth, loss of purposeful
hand movements and language skills, seizures and respira-
tory dysfunction (47). Mutations in MECP2 are also
implicated in a minority of cases presenting clinically
as Angelman syndrome, autistic spectrum disorder, non-
speciﬁc mental retardation and neonatal encephalopathy.
Decreased MeCP2 expression, in the absence of coding
region mutations, has also been observed in patients
with RTT and other neurodevelopmental disorders such
as autism, Angelman syndrome, Prader–Willi syndrome,
Down syndrome and attention-deﬁcit hyperactivity dis-
order (48,49).
More recently it has been established that an increase in
MECP2 dosage is also highly detrimental to normal cen-
tral nervous system function. Mecp2 over-expression in
mice is associated with seizures, hypoactivity and ataxia
(50). In humans, duplications of the MECP2 gene are now
also recognized among males with a phenotype of severe
mental retardation, hypotonia, recurrent respiratory infec-
tions, absence of speech development, seizures and spasti-
city (51).
Consistent with the brain-speciﬁc phenotype associated
with MECP2 dysfunction, MeCP2 is hypothesized to reg-
ulate genes involved in neuronal maturation and in main-
taining synaptic plasticity. Several neuronal-related genes
have been observed to be dysregulated in the brains of
Mecp2-mutant mice (43,52,53). Bdnf, which has been iden-
tiﬁed as a direct target of MeCP2 (Table 1), is particularly
interesting given its role in neuronal development and
plasticity, as well as the phenotypic overlap between
mice lacking Bdnf or Mecp2 (54,55). In Xenopus,
xMeCP2 regulates xHairy2a expression and is involved
in cell-fate decisions. xHairy2a is one of a family of
genes involved in repressing neuronal diﬀerentiation, and
xMeCP2-null embryos show upregulated xHairy2a and
fewer diﬀerentiated neurons. It is hypothesized that
xMeCP2 may help reduce xHairy2a expression by recruit-
ing the Sin3A-containing SMRT complex, until activation
of the Notch-Delta signalling pathway causes SMRT-
bound xMeCP2 to dissociate from the xHairy2a promoter
region (56). By contrast, MeCP2 in mice does not appear
to inﬂuence early cell-fate decisions (57), although it does
still recruit co-repressors and co-activators to genes rele-
vant to neuronal function (43,55).
THE MECP2 PROTEIN
Two MeCP2 isoforms are recognized, MeCP2_e1 (e1) and
MeCP2_e2 (e2). The e1 isoform is 498 amino acids in
length and encoded by exons 1, 3 and 4, whereas the e2
isoform is 486 amino acids long and encoded by exons 2, 3
and 4 [Figure 2; refs. (58,59)]. Upon identifying the
MeCP2_e1 isoform, Mnatzakanian et al. (58) observed
that it may be of greater clinical relevance than the e2 iso-
form, as it is the sole isoform in non-mammalian verte-
brates and its transcript is 10 times more abundant in the
human adult brain than that of e2. Furthermore, while no
RTT-associated mutations have been characterized within
exon 2, which is unique to e2, Mnatzakanian et al. (58)
were the ﬁrst to report pathogenic mutations in exon 1,
which encodes the unique N-terminal to e1. It was initially
assumed that such exon 1 mutations had no eﬀect on the e2
protein isoform, as e2 transcript levels were observed to be
unchanged (58). However, it has since been demonstrated
that exon 1 mutations may be associated with a reduction
in e2 protein levels despite the presence of e2 transcripts,
possibly through translational interference (60). Thus the
question remains of whether MeCP2_e2 is truly redundant,
or whether it may have some unique function that, when
disrupted, contributes to the RTT phenotype. In support
of the latter possibility, Dragich et al. (61) have demon-
strated that, in addition to the two isoforms having amino
termini with unique physiochemical properties, the mouse
Mecp2e1 and Mecp2e2 transcripts show distinct expression
patterns within diﬀerent brain regions and developmental
stages, and show diﬀerent preferences for alternative poly-
adenylation sites within the 30-UTR (61).
The domain responsible for speciﬁc binding to methyl-
ated CpGs (methyl-binding domain or MBD) has been
localized to an 85-amino-acid region encoded within
exons 3 and 4, which are present in both isoforms of
MeCP2 [Figure 2; ref. (20)]. The MBD has been
shown to be essential for binding of MeCP2 to hetero-
chromatin (25), as well as to unmethylated four-way
DNA junctions (38).
The residues on the N-terminal side of the MBD have an
amino acid composition very similar to the high mobility
group (HMG) proteins, which are examples of proteins in
which absence of secondary and tertiary structures permits
diﬀerent combinations of domains to perform diﬀerent
functions. On the basis of this structure, Adams et al.
(46) refer to this N-terminal domain as HMGD1. The
N-terminal region has recently been shown to interact
with the repressive chromatin regulator heterochromatin
protein 1 (HP1). This is consistent with observations
of simultaneously increased concentrations of MeCP2
and HP1a and HP1g within heterochromatin during
myogenic diﬀerentiation, however MeCP2 also binds to
HP1b which does not associate with heterochromatin
(62). The N-terminal portion, including HMGD1 and
MBD, as well as the C-terminal region have also been
shown to have an association with histone H3 methyltrans-
ferase activity (31).
The 104-amino-acid transcription repression domain
(TRD) encoded within exon 4 (26) interacts with histone
deacetylases (HDACs) and transcriptional co-repressors
Sin3A (27,28), c-Ski and N-CoR (29). HDAC1 and
HDAC2 are histone deacetylases that combine with tran-
scriptional repressors such as mSin3A to form a co-
repressor complex. The TRD also directly interferes with
assembly of the pre-initiation complex through interac-
tions with transcription factor IIB (TFIIB), a component
of the basal transcriptional machinery (30). The mainte-
nance DNA methyltransferase, Dnmt1, also associates
directly with MeCP2at the TRD, and immunoprecipi-
tated MeCP2-Dnmt1 complexes show DNA methyltrans-
ferase activity to hemimethylated DNA, implicating
MeCP2 in the maintenance of methylation patterns
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bouring sequences, are necessary for the interaction of
MeCP2 with Y box binding protein 1 (YB1). YB1,
which is an RNA-binding protein, has a number of func-
tions, including a role in alternative splicing and MeCP2,
when bound to YB1, inﬂuences splice site selection (45).
More recently, it has been demonstrated that the TRD is
also capable of interacting with DNA in vitro (46).
One of two identiﬁed nuclear localization signals (NLS)
is embedded within the TRD [see Figure 2; ref. (25)]. The
other NLS, located in HMGD2, between the MBD and
TRD, was identiﬁed by expressing human MeCP2 in
Drosophila melanogaster cells, and has not been shown
to be functional in mammalian cells (64).
Jeﬀery and Nakielny (44) identiﬁed an RG (arginine-
glycine) repeat region in HMGD2 between amino acids
160 and 200 (Figure 2). RG repeat regions are known to
mediate RNA-protein interactions, and MeCP2 was
shown to bind to mRNA and double-stranded siRNA
independent of its MBD, suggesting that MeCP2 may
have activity as part of a selective RNA–protein complex.
Further evidence in support of this claim comes from
in vivo experiments documenting an RNA-mediated inter-
action between MeCP2 and YB1 (45).
In vivo, MeCP2 interacts with chromatin via one
or more chromatin interaction domains (35,36,38,65).
A chromatin-interacting domain is likely to be positioned
within the C-terminal, as truncated MeCP2 mutants also
show impaired binding to chromatin (36,65) and induce
diﬀerent changes in chromatin architecture in vitro com-
pared to the wild-type MeCP2 (36). The tertiary structural
regions predicted by protease digestion mapping suggest
that there are two biochemically distinct C-terminal
regions, CTDa and CTDb [Figure 2; ref. (46)]. CTDa
may contribute to the recognition of methylated DNA
in chromatin (36), while CTDb encodes the WW-
domain-binding region [WDR; ref. (66)]. WW domains
are characterized by two tryptophan (W) residues sepa-
rated by 20–22 amino acids and facilitate protein–protein
interactions by recognizing proline-rich motifs (67). WW
domains are found in proteins such as the neural Wiskott–
Aldrich syndrome protein (N-WASP), and formin-binding
protein 11 (FBP11). N-WASP is involved in actin poly-
merization and cell locomotion, while FBP11 is a splicing-
factor involved in mouse limb development and also
known to interact with the Huntingtin protein implicated
in Huntington disease (66,68). FBP11 has also been shown
to interact with MeCP2, and although the precise role
of the MeCP2 WDR in vivo remains unclear, mutations
reducing WW-binding activity have been identiﬁed in
cases of RTT as well as mild to moderate mental retarda-
tion (66).
MECP2 EXPRESSION
Expression of MeCP2 is high in the brain, speciﬁcally in
neurones rather than glia, and increases progressively
during mouse embryonic and human post-natal brain
development (69–71). Immunohistochemical staining has
revealed that the timing of increasing MeCP2 expression
is correlated with the pattern of maturation of diﬀerent
brain regions and cell types (69), suggesting that MeCP2
may play a role in neuronal maturation (48,52,69,71,72).
Such a function is consistent with well-recognized features
of RTT such as apparently normal early development and
reduced brain size with decreased dendritic branching
(52,69). On the other hand, the recent ﬁnding by Guy
et al. (73) that in the Mecp2-null mouse, at least, the neuro-
logical abnormalities appear to be reversible, strengthens
that MeCP2 plays a role in the maintenance of neuronal
plasticity. The devastating neurofunctional consequences
of inappropriate up- and down-regulation of MeCP2
reveal that a more detailed understanding of the regulatory
elements inﬂuencing MeCP2 expression could yield more
insights into the pathogenic processes prompted by dys-
regulation of MeCP2 expression.
REGULATORY ELEMENTS
Liu and Francke (74) recently examined conserved ele-
ments throughout the MECP2 gene and its neighbouring
regions for regulatory activity, and identiﬁed four enhan-
cer and two silencer elements, as well as a conserved frag-
ment spanning 1080nt immediately upstream of exon 1,
which incorporates the MECP2 core promoter and at
least one positive and two negative regulatory elements
(Figure 3). The identiﬁed regulatory elements show cell-
speciﬁc activity diﬀerences. All four enhancers and two
silencers were able to interact with nuclear proteins in
gel-shift assays, and the enhancer elements contain pre-
dicted binding sites for brain-speciﬁc transcription factors.
Furthermore, three of the enhancers and both of the silen-
cers were shown to interact in cis with the core promoter,
providing further support for their potential role in tran-
scriptional regulation (74).
Promoter and5’-UTR
Contrary to the classical description of ‘TATA-dependent’
core promoters, most core promoters are now believed to
be characterized by a high GC content and multiple tran-
scription start sites (TSSs) clustered together over a stretch
of 50–100nt (2,75,76). The MECP2 core promoter
(Figure 3), as identiﬁed by Liu and Francke (74), is
embedded within a CpG island (12), and a region rich
with regulatory factor binding sites (http://genome.ucsc.
edu/). Methylation levels within the promoter region
have been shown to correlate inversely with MeCP2
expression, and signiﬁcantly increased methylation has
been observed in male autism cases relative to controls
(49). Cap analysis gene expression (CAGE) has revealed
a cluster of predicted TSSs upstream of the coding region
of exon 1, as well as several Sp1 binding sites. TSSs or TSS
clusters, when considered collectively, show distinct pat-
terns of histone modiﬁcations, chromatin accessibility and
regulatory factor binding (2,77). Consistent with these
results, ChIP data from the Ludwig Institute demonstrates
that the regions upstream and downstream of the MECP2
TSS cluster are enriched for RNA polymerase II, TAF1
and the activating histone modiﬁcations histone 3 lysine
4 dimethylation (H3K4me2) and histone 3 lysine 4
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is also seen downstream of the TSSs. Furthermore, these
ChIP results conﬁrm that the core promoter identiﬁed by
Liu and Francke (74) binds RNA polymerase II and
TAF1 in HeLa cells (Figure 3), as expected for a site
upon which the transcription initiation complex is
assembled. Polymorphisms in gene promoters can disrupt
sequence-speciﬁc interactions with regulatory molecules,
resulting in altered gene expression. A presumably rare
polymorphism within the MECP2 promoter region has
been reported in one autistic female (49), and several
other polymorphisms, including two within the core
promoter, have also been documented (http://genome.
ucsc.edu/).
3’-UTR
30-UTRs of RNA transcripts are known to have a number
of cytoplasmic functions including involvement in post-
transcriptional regulation, mRNA stability and mRNA
localization (78). The 30-UTR of MECP2 has attracted
particular attention because it is one of the longest
30-UTRs yet documented. Comparison of the mouse and
human 30-UTR genomic sequences reveals a striking pat-
tern of highly conserved regions [see Figure 4; refs.
(12,16)], a ﬁnding that has been conﬁrmed by the more
stringent measures of evolutionary sequence conservation
deﬁned by the ENCODE Consortium (79; http://genome.
ucsc.edu/). It extends over 8.5kb and contains multiple
Figure 3. MECP2 regulatory elements. (a) MECP2 regulatory elements include the cis-regulatory elements identiﬁed by Liu and Francke (74) and
the TargetScanS-identiﬁed binding site for miR-132, which has recently been shown to repress MECP2 translation (82). (b) A UCSC Genome
Browser screenshot (http://genome.ucsc.edu/, May 2004 assembly) of a 5500-bp region encompassing the promoter and exon 1 is also included. This
displays the cis-regulatory elements identiﬁed in (a) above; CpG islands; repeating elements identiﬁed by RepeatMasker; constrained elements deﬁned
by ENCODE; single nucleotide polymorphisms (SNPs) from dbSNP build 126 (March 2006 assembly); GENCODE gene annotations (v3.1 March
2007); RIKEN CAGE-predicted transcription start sites (TSSs) on the minus strand; and Yale Regulatory Factor Binding Region (RFBRs) clusters
and deserts. DNase I hypersensitivity sites are shown for HeLa (epithelioid carcinoma) and IMR90 (ﬁbroblast) cells, as identiﬁed by Duke/NHGRI.
The binding of RNA polymerase II (RNA pol II) and TATA-binding protein-associated factor 1 (TAF1); as well as the locations of histone
modiﬁcations, was determined by ChIP studies performed by Ludwig Institute/UCSD. The Sp1-binding sites were identiﬁed by Stanford in K562
(chronic myeloid leukaemia) cells.
Nucleic Acids Research, 2008, Vol. 36, No. 19 6041polyadenylation signals (Figure 2) associated with alter-
native transcripts  1.8kb,  5.4kb,  7.5kb and  10.2kb
in length (12,14,16,69). The shortest MECP2 transcript
(1.8kb) uses the canonical 50 – AATAAA – 30 polyadenyl-
ation signal, which is usually found 10–30 nucleotides
upstream of the cleavage site and is bound by cleavage
and polyadenylation speciﬁcity factor [CPSF; ref. (80)].
The longest transcript (10.2kb) instead uses the less-eﬃ-
cient sequence 50 – TATAAA – 30 (12,16). Both polyade-
nylation signal sequences are followed by a GT-rich region
(16), which is known to bind cleavage stimulation factor
(CstF), involved in the polyadenylation and 30-end
cleavage of pre-mRNAs (80).
The alternative MECP2 transcripts show quantitative
diﬀerences in diﬀerent tissues (12,14,16,17,69) as well
as in diﬀerent stages of mouse embryonic development
(16) and human post-natal brain development (48,71).
Given the unique expression patterns of each transcript,
it is likely that the 30-UTR and the alternative transcripts
have biological signiﬁcance. The 30-UTR was hypothe-
sized to play a role in transcript stability, as it contains
conserved regions predicted to inﬂuence RNA folding
(16), as well as an AT-rich sequence (12,16) known to
inﬂuence mRNA stability (81). However, a signiﬁcant dif-
ference in the half lives of MECP2 long and short tran-
scripts has not been observed (12), and no simple
relationship has been found between alternative tran-
scripts and protein levels across a range of tissues (69)
or within individual cells (48). Although a quantitative
reduction in the 10.2-kb transcript is seen in parallel
with increasing MeCP2 during post-natal brain develop-
ment (71), this inverse relationship between levels of
MeCP2 protein and long 30-UTR usage does not hold at
a cellular level, where neurones with abundant MeCP2
Figure 4. Features within the MECP2 genomic region and adjacent genes. A UCSC Genome Browser screenshot of a 160 000-nt region encom-
passing MECP2 and its immediate neighbouring genes (http://genome.ucsc.edu/, May 2004 assembly) is displayed. The tracks displaying regulatory
elements, CpG islands, repetitive elements, constrained elements, SNPs, GENCODE-annotated genes, TSSs, RFBR clusters and deserts, DNase I
hypersensitivity, regulatory potential; RNA pol II, TAF1, Sp1 and the histone modiﬁcations are all as deﬁned in Figure 3. Also shown are
TargetScanS-predicted miRNA-binding sites (March 2006 assembly) deletion-insertion polymorphisms (DIPs) deﬁned by NHGRI, regulatory poten-
tial as predicted by ESPERR, CCCTC-binding factor (CTCF) binding sites identiﬁed by Sanger in GM06990 (lymphoblastoid) cells and binding sites
for CCAAT/enhancer binding protein epsilon (CEBPe), CTCF, P300, PU1 and retinoic acid receptor, alpha (RARA) identiﬁed by Aﬀymetrix in
HL60 (promyelocytic leukaemia) cells.
6042 Nucleic Acids Research, 2008, Vol. 36, No. 19protein have increased levels of the 10.2-kb transcript
(17,48).
In addition to protein–protein and protein–DNA inter-
actions, gene expression may also be regulated by RNA–
protein, RNA–RNA and RNA–DNA interactions. One
mechanism by which 30-UTRs are known to participate
in post-transcriptional regulation is through interactions
with proteins or microRNAs (miRNAs). miRNAs are
small RNA molecules that may be derived from intronic
regions, transposons and processed pseudogenes, as well
as exons, and are known to suppress translation by bind-
ing to mRNA (1). The MECP2 30-UTR contains
52 TargetScanS-predicted miRNA-binding sites (http://
genome.ucsc.edu/). Observing that microRNA 132
(miR132) is highly expressed in the brain, Klein et al.
(82) have recently proposed that miR132, which interacts
with the 30-UTR of the long MECP2 transcript (Figure 3),
may function as a key regulator of MeCP2 expression.
miR132 is induced by BDNF and CREB-1, which are
both targets of MeCP2-mediated gene regulation
(Table 1), suggesting that miR132 may be involved in feed-
back loops regulating MeCP2 protein levels (82).
Other recently defined features within theMECP2
genomic region
Until recently, transcripts from the MECP2 gene locus
were limited to a 76-kb interval positioned in the 125-kb
gap between the neighbouring genes, encoding the
interleukin-1 receptor (IRAK1) and a long-wavelength
sensitive opsin (OPN1LW). The interval to OPN1LW,
which is transcribed from the opposite strand, is 50kb
and the interval to the annotated exon 1 of IRAK1
(Gencode v3.1, March 2007), which is transcribed in the
same direction as MECP2,i s 2kb. RACE experiments
conducted as part of ENCODE have identiﬁed a novel
50exon in testis that is located  40-kb upstream of the
MECP2 promoter (83), and greatly reduces the size of
the intergenic interval at the telomeric end of MECP2
(Figure 4). Interestingly, the region surrounding the
newly identiﬁed distal exon contains a CpG island, binds
RNA polymerase II and TAF1, and is enriched for the
histone modiﬁcations H3K4me2, H3K4me3 and H3ac,
although to a lesser extent than the region surrounding
the currently annotated exon 1 of MECP2.
ENCODE has also provided a large resource of com-
parative genomics data that can assist in the identiﬁcation
of additional MECP2 functional elements. 4.9% of the
nucleotides in the ENCODE regions were identiﬁed as
constrained by at least two (out of a possible three) pro-
grams when using at least two of three multiple sequence
alignments (2,79). DNase I hypersensitivity is a marker
of regions likely to regulate transcriptional activation,
and the region around the newly identiﬁed upstream
exon displays DNaseI hypersensitivity. It is also predicted
by the ESPERR (Evolutionary and Sequence Pattern
Extraction through Reduced Representation) program
to be regulatory, but only small segments are conserved
across species. This is consistent with the observation
across the ENCODE regions that although over 50% of
non-coding functional elements overlap constrained
elements, the proportion of constrained nucleotides
within these elements is <10%. This compares with a con-
straint of almost 70% among bases within coding regions
(2,79). In light of the extensive additional transcription
revealed by ENCODE, it is also interesting to note the
binding of RNA polymerase II and TAF1 to several intro-
nic regions corresponding to the 50-termini of non-coding
exons.
It is notable that the novel transcribed regions identiﬁed
within introns of MECP2 also do not have the high evolu-
tionary constraint seen in coding exons, and several
of these, as well as a surprisingly large proportion of
non-coding functional elements identiﬁed throughout
other ENCODE regions, do not show evidence of evolu-
tionary constraint in this stringent analysis. Margulies
et al. (79) suggest that this discrepancy may be explained
by possibilities such as elements performing functions that
oﬀer no evolutionary advantage, or not requiring con-
straint at the primary sequence level. Another alternative,
which they suggest, is that these elements may have
evolved more recently and so may be conserved across
primates but not other mammals (79). By contrast, all
but one of the cis-regulatory elements identiﬁed by Liu
and Francke (74) overlap these stringently deﬁned con-
strained elements. It should be noted also that a large
proportion of constrained sequences and predicted regu-
latory regions within MECP2 do not overlap any of the
functional elements that have been described to date, pro-
viding an indication of the extent of the pool of unchar-
acterized functional elements.
Of the novel GENCODE-annotated MECP2 tran-
scripts, only one has an open reading frame annotated
in the UCSC genome browser (http://genome.ucsc.edu),
making it likely that the others may function as regulatory
ncRNAs. Transcription of ncRNAs from the mammalian
genome is an increasingly recognized phenomenon (2,84),
and ncRNAs are being implicated in diverse cellular pro-
cesses, including regulation of various levels of gene
expression, regulation of localization and function of
other molecules and in the targeting of generic enzymes
to speciﬁc genomic loci (1). Several recently discovered
ncRNAs that have not been well-characterized function-
ally, have been shown to have regulated expression pat-
terns, suggesting that many ncRNAs have important
functions that are yet to be determined (85–88). MeCP2
has been reported to interact with RNA (44), and tissue-
speciﬁc non-coding transcripts from MECP2 or other
genes may be able to regulate MeCP2 expression or func-
tion in a tissue-speciﬁc manner. In view of these insights, it
seems possible that mutations disrupting the secondary
structures of regulatory ncRNAs from MECP2 may
result in disturbed MeCP2 expression and present clini-
cally with a similar phenotype to those patients who
have MECP2 coding-region mutations. As MeCP2 is
implicated in neurodevelopmental disorders, the novel
transcribed region within intron 1 (Figure 1) that has
been detected in brain is of particular interest with
regard to disease-causing capacity. Further knowledge of
the cellular localization, molecular interactions and quali-
tative or quantitative diﬀerences between RTT-patients
and unaﬀected controls may provide additional insights
Nucleic Acids Research, 2008, Vol. 36, No. 19 6043into the biological functions and clinical relevance of these
newly discovered ncRNAs.
Other DNase I hypersensitivity sites have a distribution
within MECP2 that varies between diﬀerent cell lines
(Figure 4), suggesting the existence of cell-speciﬁc regula-
tory elements. Similar to the chromatin signature patterns
observed at TSSs or TSS clusters, the DNase I hypersen-
sitivity sites located downstream from the major TSS clus-
ter display enrichment for H3ac. However, absence of
H3K4me3 or RNA polymerase II enrichment, as well as
the presence of H4ac, distinguishes these from the
TSS-related DNase I hypersensitivity sites (2,77).
CCCTC-binding factor (CTCF) is a transcription factor
known to be required for insulator function (89). A CTCF-
bindingsiteislocatednearthemost50-terminalofthenovel
MECP2 transcripts identiﬁed by ENCODE, while another
is positioned downstream within the IRAK1 gene. Another
CTCF-binding site was reported deep within intron 2 by
Kim et al. (89) in ﬁbroblasts, and conﬁrmed by the Sanger
Institute in a lymphoblastoid cell line (http://genome.ucsc.
edu/). This intronic CTCF-binding site displays DNaseI
hypersensitivity in the lymphoblastoid cell line, as well as
in HeLa cells and ﬁbroblasts. Using the HL60 (promyelo-
cyctic leukaemia) cell line, Aﬀymetrix identiﬁed another
intronic CTCF-binding site that also binds PU1 and the
alpha chain of the retinoic acid receptor (RARA; Figure 4;
http://genome.ucsc.edu/).
While ENCODE has provided a tremendous amount of
information concerning potential regulatory elements
within MECP2, further work is still needed to meaning-
fully interpret and integrate these datasets. From the
perspective of human disease arising from MECP2 expres-
sion abnormalities, which is a predominantly neuronal
phenotype, a particular limitation of ENCODE is that
chromatin immunoprecipitation results are derived from
non-neuronal cell lines. While the mechanisms that regu-
late MECP2 expression within central nervous system tis-
sues may diﬀer from those in the cell lines represented to
date, ENCODE provides a shortlist of candidate regula-
tory regions. The challenge now is to identify which of
these regulatory elements are functional in neuronal
cells, and whether any of these can assist in the develop-
ment of new diagnostic or management strategies for
patients with dysregulated MECP2 expression or
function.
CONCLUSION
Since the discovery that many RTT cases are due to muta-
tions in MECP2, our knowledge of the structure and func-
tion of genomic elements within this relatively small gene
has advanced signiﬁcantly. It is now appreciated that
MECP2 probably has several biological functions and
mechanisms of action, including the recruitment of
chromatin-modifying enzymes. Evidence of precise spatial
and temporal regulation of an increasing diversity of
expression patterns of the two MeCP2 protein isoforms
underlines the importance of the emerging details of
epigenetic signatures across the MECP2 genomic region.
In this regard, it is also interesting to note the numerous
recently identiﬁed highly conserved non-coding regions,
including those within the long 30-UTR and intron 2.
The discovery of transcripts arising from novel intronic
exons, as well as from what had been regarded as the
upstream intergenic region, is particularly exciting in
view of the growing recognition of the existence and func-
tional signiﬁcance of ncRNAs. Such advances in our
understanding of gene biology may aid the process of
characterizing precisely how MECP2 dysfunction at
the molecular and cellular level leads to neurological
phenotypes.
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